Alert: Rating Upgrade (11/17/23)-Blueprint Medicines Corp (NASDAQ: BPMC).


Stock Rating Upgrade

The Value Trend Rating for Blueprint Medicines Corp (NASDAQ: BPMC) improved in recent days from D to C reflecting improving fundamentals and high Appreciation Potential. Details supporting this higher rating are included in our next report.


Recent Price Action

Blueprint Medicines Corp (NASDAQ: BPMC) stock increased 1.7% on 11/17/23. The shares closed at $63.66. The stock has been exceptionally strong relative to the market over the last nine months and has risen 11.2% during the last week.

Current PriceTarget Research Rating

Reflecting future returns on capital that are forecasted to be in line with the cost of capital, BPMC is expected to continue to be Value Creation neutral.

Blueprint Medicines has a current Value Trend Rating of C (Low Neutral). This VT Rating improved in recent days from D previously. The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Blueprint Medicines has a very low Appreciation Score of 4 but a good Power Rating of 84, and the Low Neutral Value Trend Rating results.

Be the first to comment

Leave a Reply

Your email address will not be published.